Crispr Therapeutics Board Director Simeon George Purchases $51.5 Million in Shares
PorAinvest
domingo, 20 de julio de 2025, 1:51 am ET1 min de lectura
CRSP--
The purchase was disclosed in an SEC filing, indicating that Simeon bought 989,812 shares at a price of $52.03 each [4]. This substantial investment by an insider has sparked interest among investors, contributing to the stock's recent performance.
Analysts have mixed views on CRISPR Therapeutics' future prospects. While the average target price is projected at $80.84, with high estimates at $268.00 and lows at $32.00, the average brokerage recommendation is a solid 2.2, translating to an "Outperform" rating [3]. GuruFocus offers a more conservative estimate, setting the GF Value at $36.68, implying a potential downside of 41.66% from the current price of $62.875 [3].
Despite the stock's recent gains, CRISPR Therapeutics reported a net loss of $136 million in the first quarter of 2025, with revenues jumping by 71.6% to $865 million [4]. The company is expected to release its second quarter earnings performance in the first week of August 2025.
References:
[1] https://www.sec.gov/Archives/edgar/data/1674416/000095017025096666/xslF345X05/ownership.xml
[2] https://seekingalpha.com/news/4468897-crispr-director-george-buys-515m-of-shares
[3] https://www.gurufocus.com/news/2987913/crsp-surges-after-major-stock-purchase-by-board-director
[4] https://finance.yahoo.com/news/crispr-therapeutics-crsp-soars-18-181654598.html
Crispr Therapeutics (NASDAQ:CRSP) disclosed a $51.5 million stock purchase by board director Simeon George in an SEC filing. The company's stock surged as much as 21% on Friday, marking its biggest intraday gain since February, and is now up around 58.4% year-to-date.
Crispr Therapeutics (NASDAQ:CRSP) experienced a significant stock surge following a major insider purchase. On July 16, 2025, the company's board director, George Simeon, purchased $51.5 million worth of shares [2]. The stock surged by as much as 21% on Friday, marking its biggest intraday gain since February [3]. As a result, the stock is now up around 58.4% year-to-date [2].The purchase was disclosed in an SEC filing, indicating that Simeon bought 989,812 shares at a price of $52.03 each [4]. This substantial investment by an insider has sparked interest among investors, contributing to the stock's recent performance.
Analysts have mixed views on CRISPR Therapeutics' future prospects. While the average target price is projected at $80.84, with high estimates at $268.00 and lows at $32.00, the average brokerage recommendation is a solid 2.2, translating to an "Outperform" rating [3]. GuruFocus offers a more conservative estimate, setting the GF Value at $36.68, implying a potential downside of 41.66% from the current price of $62.875 [3].
Despite the stock's recent gains, CRISPR Therapeutics reported a net loss of $136 million in the first quarter of 2025, with revenues jumping by 71.6% to $865 million [4]. The company is expected to release its second quarter earnings performance in the first week of August 2025.
References:
[1] https://www.sec.gov/Archives/edgar/data/1674416/000095017025096666/xslF345X05/ownership.xml
[2] https://seekingalpha.com/news/4468897-crispr-director-george-buys-515m-of-shares
[3] https://www.gurufocus.com/news/2987913/crsp-surges-after-major-stock-purchase-by-board-director
[4] https://finance.yahoo.com/news/crispr-therapeutics-crsp-soars-18-181654598.html

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios